GK-136901 is a first-in-class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitor. References: Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol. 2012 May-Jun;56(5-6):216-31. doi: 10.1016/j.vph.2012.02.012. Epub 2012 Mar 3. Review. PubMed PMID: 22405985; PubMed Central PMCID: PMC3378316.

纯度：≥98%

CAS：1062624-71-8